Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026

ACRS vs LYRA: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ACRS Captures Overall Composite Edge (44.7 HOLD vs 52.2 HOLD), While LYRA Leads 3–2 on Growth & Valuation Pillars

ACRS Overall Winner 6-Pillar Tally: ACRS 2 – 3 LYRA (1 Tie) Matrix Metrics: ACRS 6 – 1 LYRA

As of Nov 17, 2026, Aclaris Therapeutics, Inc. (ACRS) captures the overall head-to-head institutional edge over Lyra Therapeutics, Inc. (LYRA) on higher Unified Composite conviction (44.7/100 HOLD vs. 52.2/100 HOLD) after splitting the core matrix 6–1 (led by Growth & Scale, Profitability & Quality), while LYRA wins 3–2 across the 6-pillar growth and valuation breakdown. ACRS trades at $3.35 (N/M Forward P/E, -1412.4% operating margin) versus LYRA at $0.49 (N/M Forward P/E, -25032.0% operating margin).

  • Composite vs. Pillar Nuance: While LYRA currently prints a higher short-term Unified Composite Score (52.2/100 HOLD vs. ACRS 44.7/100 HOLD), ACRS captures the overall institutional head-to-head verdict (6–1 matrix metrics and 2–3 across the 6 pillars) due to superior fundamental profitability (-1412.4% vs. -25032.0% operating margin) and revenue trajectory (-55.1% vs. -87.2% YoY).
  • Technical & Structure Timing Caution: ACRS is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 37.0); meanwhile LYRA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 21.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ACRS vs LYRA
ACRS NASDAQ Head-to-Head Winner
Aclaris Therapeutics, Inc.
Pharmaceutical Preparations
$3.35
-7.21% 1D
Market Cap $621.8M
TTM Revenue $6.4M
Forward P/E N/M
Beta / 30D Vol 1.56β · 74% Vol
Unified Composite Score
44.7 / 100 HOLD
Tech 41.0 Fund 54.0 Flow 64.0 Mom 70.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -17.3%), weak momentum, RSI 37
RSI-14: 37.0 · SMA20: $3.86 · SMA50: $4.33
LYRA NASDAQ
Lyra Therapeutics, Inc. Common Stock
Surgical & Medical Instruments & Apparatus
$0.49
-62.5% 1D
Market Cap $2.3M
TTM Revenue $600,000
Forward P/E N/M
Beta / 30D Vol 0.33β · 248% Vol
Unified Composite Score
52.2 / 100 HOLD
Tech 60.0 Fund 56.0 Flow 50.0 Mom 59.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -35.3%), weak momentum, RSI 21
RSI-14: 21.5 · SMA20: $1.27 · SMA50: $1.82

6-Pillar Scorecard Institutional Category Breakdown (ACRS 2 – 3 LYRA)

Columns: Metric · ACRS · LYRA
1. Valuation Multiples LYRA
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 97.1x 3.9x
2. Growth & Scale ACRS
Revenue Growth (YoY) -55.1% -87.2%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $6.4M $600,000
Market Cap $621.8M $2.3M
3. Profitability & Quality ACRS
Gross Margin N/A N/A
Operating Margin -1412.4% -25032.0%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -55.5% -404.5%
4. Balance Sheet & Cash Flow LYRA
Cash Generation (TTM) -$75M -$32M EBITDA
Cash Flow Margin N/A N/A
Net Cash / Leverage $1.11 Book/Sh · -55.5% ROE -404.5% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning LYRA
Options Structure Phase BREAKDOWN UNCLASSIFIED
Current IV / %ile 60.7% (1st %ile) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ACRS (6) vs LYRA (1)
Institutional Metric ACRS LYRA Criterion Row Edge
Market Capitalization
Scale
$621.8M $2.3M Larger Scale ACRS
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
-55.1% -87.2% Higher Growth ACRS
Operating Margin (TTM)
Profitability
-1412.4% -25032.0% Higher Margin ACRS
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-55.5% -404.5% Higher ROE ACRS
52-Week Range Position
Momentum
25% ($2–$7) 1% ($0–$38) Stronger Trend ACRS
Beta / 30D Volatility
Risk Regime
1.56β · 74% Vol 0.33β · 248% Vol Lower Realized Risk ACRS
Unified Institutional Score
Composite Signal
44.7 / 100 (HOLD) 52.2 / 100 (HOLD) Higher Composite LYRA
Trailing 12M Revenue (USD)
Operating Scale
$6.4M $600,000 FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 97.1x EV/Rev N/M PEG · 3.9x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$75M ($1.11 Book/Sh · -55.5% ROE) -$32M EBITDA (-404.5% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ACRS +73.81 pp
ACRS: +11.31% · LYRA: -62.5%
3M Horizon ACRS +98.93 pp
ACRS: +11.31% · LYRA: -87.62%
6M Horizon ACRS +135.55 pp
ACRS: +48.41% · LYRA: -87.14%
1Y Horizon ACRS +135.55 pp
ACRS: +48.41% · LYRA: -87.14%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period ACRS Revenue LYRA Revenue ACRS Op. Margin LYRA Op. Margin Margin Leader
FY2018 $10M N/A -1378.3% N/A ACRS
FY2019 $0M N/A -2627.3% N/A ACRS
FY2020 $10M N/A -785.4% N/A ACRS
FY2021 $10M $0M -1327.1% -15303.5% ACRS
FY2022 $30M $0M -302.0% -4131.0% ACRS
FY2023 $30M $0M -311.6% -4308.1% ACRS
FY2024 $20M $0M -758.2% -6280.8% ACRS
FY2025 $10M $0M -975.9% -7794.5% ACRS

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ACRS BREAKDOWN
130d in phase · OBV NEUTRAL
Current IV 60.7%
IV Percentile 1st %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact ACRS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
LYRA UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact LYRA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ACRS Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $621.8M market capitalization and -1412.4% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
LYRA Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $2.3M market capitalization and -25032.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ ACRS vs LYRA Key Questions & Quantitative Answers

As of Nov 17, 2026, Aclaris Therapeutics, Inc. (ACRS) captures the overall head-to-head institutional edge over Lyra Therapeutics, Inc. (LYRA) on higher Unified Composite conviction (44.7/100 HOLD vs. 52.2/100 HOLD) after splitting the core matrix 6–1 (led by Growth & Scale, Profitability & Quality), while LYRA wins 3–2 across the 6-pillar growth and valuation breakdown. ACRS trades at $3.35 (N/M Forward P/E, -1412.4% operating margin) versus LYRA at $0.49 (N/M Forward P/E, -25032.0% operating margin). Composite vs. Pillar Nuance: While LYRA currently prints a higher short-term Unified Composite Score (52.2/100 HOLD vs. ACRS 44.7/100 HOLD), ACRS captures the overall institutional head-to-head verdict (6–1 matrix metrics and 2–3 across the 6 pillars) due to superior fundamental profitability (-1412.4% vs. -25032.0% operating margin) and revenue trajectory (-55.1% vs. -87.2% YoY). Technical & Structure Timing Caution: ACRS is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 37.0); meanwhile LYRA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 21.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

ACRS leads the Growth & Scale pillar: ACRS posts -55.1% YoY revenue growth and +0.0% YoY earnings growth on $6.4M TTM revenue (N/A gross margin, -1412.4% operating margin), compared with LYRA at -87.2% YoY revenue growth and +0.0% YoY earnings growth on $600,000 TTM revenue (N/A gross margin, -25032.0% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), ACRS cumulative revenue shifted +0.0% while LYRA shifted N/A. In operating R&D and SG&A reinvestment, ACRS deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for LYRA.

LYRA screens cheaper on headline valuation multiples. ACRS trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 97.1x EV/Revenue (unreported FCF margin), whereas LYRA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 3.9x EV/Revenue (unreported EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ACRS (-55.5% ROE) versus LYRA (-404.5% ROE) capital efficiency.

In options market volatility and institutional positioning, ACRS carries 60.7% implied volatility (1st %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.56β · 74% Vol realized risk). By comparison, LYRA carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.33β · 248% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.